In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Centogene NV (CNTG – Research Report), with a price target of $1.50. The company’s shares opened today at $1.07.
Chen covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, Oculis Holding, and EyePoint Pharmaceuticals. According to TipRanks, Chen has an average return of -31.9% and a 22.49% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Centogene NV with a $1.50 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.52 and a one-year low of $0.61. Currently, Centogene NV has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Read More on CNTG:
- CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
- CENTOGENE Reports First Half 2023 Financial Results
- CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
- Centogene announces publication on utility of lyso-Gb1
- Centogene receives noncompliance notification from Nasdaq
